CytoSorbents Leads a New Era in Sepsis Treatment CytoSorbents highlights the vital and evolving role of CytoSorb in the treatment of sepsis and septic shock ahead of its World Sepsis Day Global Webinar on September 10 th

CytoSorbents Leads a New Era in Sepsis Treatment

CytoSorbents highlights the vital and evolving

role of CytoSorb in the treatment of sepsis and septic shock ahead of its World Sepsis Day Global Webinar on September 10th

PRINCETON, N.J., July 31, 2025 - CytoSorbents

Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery

using blood purification, highlights new studies that demonstrate the vital and evolving role of CytoSorb therapy in the treatment

of sepsis and septic shock - among the deadliest challenges in critical care medicine. Recent data demonstrate early and intensive

use of CytoSorb therapy improves clinical outcomes for patients suffering from these conditions. Today, the Company provides an overview

of CytoSorb's unique approach and the evolving data supporting its use, in advance of its September 10, 2025 World Sepsis Day Global

Webinar - being held in commemoration of Sepsis Awareness Month and World Sepsis Day in September. Dr. Phillip Chan, MD, PhD, Chief

Executive Officer, will host a special presentation with physician-user guests to discuss CytoSorb therapy best practices and its impact

in the fight against sepsis.

Dr. Chan explains, "For more than a decade,

CytoSorbents has partnered with clinicians and scientists to improve the treatment of sepsis and septic shock by supplementing traditional

antibiotic therapy with the powerful, broad-spectrum blood purification capability of CytoSorb. While antibiotics target the source of

infection, CytoSorb addresses the other major drivers of septic shock, including severe inflammation, shock, capillary leak, fluid overload,

and organ failure. Recent studies reinforce that, like antibiotics, CytoSorb therapy is most effective when initiated early, applied intensively,

and continued for an appropriate duration. Backed by a strong safety record and many peer-reviewed publications, CytoSorbents and collaborators

are helping to solve this critical problem that claims millions of lives around the world annually."

Sepsis and Septic Shock: A Life-Threatening

Crisis Driven by Inflammation

Sepsis is a complex, life-threatening condition

where the inflammatory response to a serious infection can spiral out of control, fueled by the excessive production of cytokines (cytokine

storm), bacterial toxins, and other inflammatory agents. Left unchecked, this inflammation can lead to septic shock - an often

fatal complication marked by circulatory collapse and a lethal drop in blood pressure, the failure of multiple vital organs, and fluid

overload - essentially drowning the patient from within. Each year, sepsis and septic shock afflict an estimated 49 million people

worldwide, killing 11 million, accounting for up to 20% of all global deaths.

Despite decades of effort, standard treatments

of septic shock such as antibiotics, fluids, vasopressors, and organ support are often not enough, with mortality rates of 30-50% that

can escalate rapidly with multiple organ failure. Survivors often face long-term disability and shorter life spans. The complexity of

sepsis has led to the failure of hundreds of therapy candidates and over 100 Phase II and III clinical trials over many decades -

underscoring the urgent need for more effective solutions.

CytoSorb: A Broad-Spectrum Solution with

CytoSorb is a first-in-class, extracorporeal

blood purification therapy approved in the European Union with nearly 300,000 human treatments across more than 70 countries globally.

It uses advanced porous polymer beads to remove a wide array of toxic substances directly from the bloodstream, including, for example,

inflammatory cytokines and mediators, bacterial toxins, and other damaging molecules that contribute to inflammation, shock, blood vessel

damage, and organ injury.

However, what sets CytoSorb apart from other approaches,

that often simply focus on a single target or pathway, is a comprehensive, multi-faceted approach to the core problems of sepsis and septic

shock. Based on a substantial body of published, peer-reviewed literature, CytoSorb can:

This broad-spectrum approach helps to support

five essential treatment goals of CytoSorb in septic shock:

Like antibiotics, CytoSorb works best when used

early, intensively, and at the right dose - the foundation of the Company's "Right patient, Right Timing, Right Dosing"

educational campaign.

Positive Clinical Results Backing Early

and Intensive CytoSorb Use

CytoSorbents' clinical

impact is supported by hundreds of peer-reviewed publications in many different

clinical applications such as sepsis, including data from the COVID-19 pandemic, where CytoSorb was granted U.S. FDA

Emergency Use Authorization in critically ill COVID-19 patients with respiratory failure. In the 100-patient,

multi-center registry of U.S. COVID-19 patients on CytoSorb and ECMO, published in the journal Critical Care (2023),

where all had refractory respiratory failure and sepsis with 76% in septic shock, Hayanga and colleagues

reported 74% 90-day survival, that rose to 82%

in those treated early. This significantly outperformed published U.S.

survival benchmarks of approximately 50% when CytoSorb was not used.

A separate, retrospective

study of 175 septic shock patients recently published by Berlot and team in the Journal of Intensive Care Medicine (2025)

demonstrated that early and intensive CytoSorb

use ( 3 cartridges within 2-3 days) nearly doubled survival

rates (70% observed vs. 37% predicted), with strong correlations between clinical benefit and treatment intensity. The study

also corroborated the findings of another 75 septic shock patient retrospective study published by Schultz, et al. (2021) in the Journal

of Critical Care that correlated survival with higher volumes of blood treated, highlighting that duration of treatment is critically

Further strengthening the evidence base, the first

meta-analysis of 744 patients with septic shock by Steindl and colleagues from Charit Berlin Hospital was recently reported

in the Journal of Clinical Medicine (2025) comparing 449 patients treated

with CytoSorb and standard of care versus 295 control patients receiving standard of care alone. The study demonstrated statistically

significant improvements in hemodynamics, vasopressor requirements, and survival compared to control patients, where CytoSorb:

Meanwhile, results from the first

150 patients enrolled into the international, prospective COSMOS (CytOSorb treatMent Of critically ill patientS) critical care registry

by Ferrer and collaborators was recently published in the Journal of Intensive Medicine (2025), where 58% of patients had septic

shock, highlighting improved mortality compared with risk-based predictions and significant improvements in oxygenation, shock reversal,

fluid balance, and lactate levels before and after use of CytoSorb.

Overall, these results highlight CytoSorb's

ability to intervene across the pathophysiology of septic shock, setting it apart from previous drug and device-based approaches that

failed to show consistent benefit.

Dr. Chan concluded, "Septic shock remains

one of the most devastating and complex challenges in critical care. Despite decades of research, outcomes remain poor with limited treatment

options. CytoSorb, guided by the experience and insight of clinicians and scientists around the world, is helping that change that. With

an ever-expanding body of published clinical evidence - including hundreds of peer-reviewed studies such as those mentioned above, real-world

data, and impactful success stories, CytoSorb continues to evolve as a powerful therapy to treat critical illnesses such as septic shock,

particularly when used early, intensively, and of the right duration - just like antibiotics. In treating the sickest patients in

the hospital, we are proud of our mission of working to save lives together."

For more detailed information, follow our new

septic shock blog series where CytoSorbents delves into greater detail on these points, found here.

Meanwhile, watch videos from healthcare providers from around the world who detail their first-hand experiences with CytoSorb in the

treatment of septic shock and other critical illnesses in our "Voices Around the World" segment, found here.

Please join us for our World Sepsis Day Global Webinar on September 10, 2025 (details to come), where we will explore best practices

in the treatment of septic shock with CytoSorb with some of the pioneering clinicians who are fighting this battle daily on the front

About CytoSorbents Corporation (NASDAQ: CTSO)

Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through

blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer

beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges

filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy

or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body,

through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a

number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic

surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that

can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis,